<DOC>
	<DOCNO>NCT01475851</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety once-daily treatment GSK548470 300 mg Japanese patient compensate chronic hepatitis B poor response drug .</brief_summary>
	<brief_title>Phase 3 Study GSK548470 Patients With Compensated Chronic Hepatitis B With Poor Response Other Drugs</brief_title>
	<detailed_description>This multicenter , open-label study Japanese patient compensate chronic hepatitis B poor response drug order evaluate efficacy safety GSK548470 administer dose 300 mg daily . The target sample size set 32 subject . The primary objective evaluate efficacy safety once-daily treatment GSK548470 300 mg subject compensate chronic hepatitis B poor response drug . The secondary objective evaluate long-term efficacy safety once-daily treatment GSK548470 300 mg.To evaluate efficacy safety GSK548470 study , subject receive combination lamivudine ( LAM ) adefovir pivoxil ( ADV ) switch combination LAM GSK548470 , subject entecavir hydrate ( ETV ) without ADV switch combination ETV GSK548470 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>The ability understand sign write informed consent form 16 69 year age time inform consent Females childbearing potential must negative pregnancy test agree avoidance pregnancy Subject must show QTc &lt; 450 millisecond ( msec ) &lt; 480msec Bundle Branch Block Chronic HBV infection , define positive serum HBsAg least 6 month Subjects currently treat LAM/ADV , ETV ETV/ADV great 24 week Chronic hepatitis B ; HBV NDA &gt; = 4 log10 copies/mL , Chronic hepatitis B cirrhosis ; HBV NDA &gt; = 3 log10 copies/mL Serum ALT &lt; = 10 × ULN Creatinine clearance &gt; = 70 mL/min Haemoglobin &gt; = 8 g/dL WBC &gt; = 1,000 /mm3 Decompensated liver disease Coinfection HIV HCV Autoimmune hepatitis rather chronic hepatitis B Subject serious complication Received plan solid organ bone marrow transplantation Has proximal tubulopathy History hypersensitivity nucleoside and/or nucleotide analogues Evidence hepatocellular carcinoma diagnostic imaging screen and/or serum αfetoprotein &gt; 50 ng/mL screen History HCC Received interferon HB vaccine therapy within 24 week prior initiation Received overdose NSAIDs , exclude temporary topical use , within 7 day prior initiation Received drug injection contain glycyrrhizin main component within 4 week prior initiation Received drug cause renal impairment , competitor renal excretion , immunosuppressant , chemotherapeutics and/or corticosteroid within 8 week prior initiation Participation another clinical study within 6 month study entry plan participation another clinical study entry study Woman pregnant , lactate , possibly pregnant planning pregnancy study period Psychiatry disorder cognitive disorder may affect subject ability give inform consent follow specify study procedure History alcohol drug abuse Any condition situation may interfere subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Tenofovir disoproxil fumarate , compensate chronic hepatitis B</keyword>
</DOC>